The global chronic hepatitis B market was valued at $4,589.8 million in 2021 and is projected to reach $6,213.15 million by 2031, registering a CAGR of 3.0% from 2022 to 2031. Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Hepatitis B can cause chronic infection and increases the risk of death from cirrhosis and liver cancer.
The increase in rate of hepatitis B and rise in awareness about hepatitis B drive the growth of the market. For instance, according to a report of World Health Organization (WHO) published in June 2022, globally, an estimated 296 million people were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. Thus, increase in prevalence of hepatitis B globally boosts the growth of the market.
In addition, factors such as increase in blood donation and rise in blood transfusion rate foster the growth of the market. The blood transfusion is a leading cause of hepatitis B virus transmission. For instance, as per the report of World Health Organization (WHO) published in May 2022, about 118.54 million blood donations are made worldwide. About 40% of these are collected in high-income countries. The World Health Organization (WHO) recommends that all blood donations should be screened for infections prior to use. Screening for HIV, hepatitis B, hepatitis c, and syphilis should be mandatory.
Moreover, increase in R&D activities for development of novel chronic hepatitis B treatment, rise in the U. S. food & drug administration (FDA) approvals and novel product launch in the market by key players boost the market growth. For instance, in June 2022, glaxosmithkline (GSK), a science-led global healthcare company, announced the interim results from the B-Clear phase IIb trial showing that bepirovirsen, an investigational antisense oligonucleotide treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA after 24 weeks’ treatment in people with chronic hepatitis B (CHB). Furthermore, advancements in hepatitis B treatment and rise in diagnosis rate further contribute toward the market growth. However, high cost of chronic hepatitis B drugs is projected to hinder the growth of the market.
The chronic hepatitis B market is segmented on the basis of drug class, gender, distribution channel, and region. By drug class, the market is fragmented into antivirals, and immune modulators. By gender, the market is classified into male, and female. The male segment is further divided into adult and geriatric. The female segment is further divided into adult and geriatric. By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Biocon Inc, Cipla Limited, Dr. Reddy's Laboratories, Gilead Sciences, Inc., Novartis AG, Reliance Life Sciences, Sun Pharmaceutical Industries Limited, Teva pharmaceuticals, Viatris Inc and Zydus Cadila.
The increase in rate of hepatitis B and rise in awareness about hepatitis B drive the growth of the market. For instance, according to a report of World Health Organization (WHO) published in June 2022, globally, an estimated 296 million people were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. Thus, increase in prevalence of hepatitis B globally boosts the growth of the market.
In addition, factors such as increase in blood donation and rise in blood transfusion rate foster the growth of the market. The blood transfusion is a leading cause of hepatitis B virus transmission. For instance, as per the report of World Health Organization (WHO) published in May 2022, about 118.54 million blood donations are made worldwide. About 40% of these are collected in high-income countries. The World Health Organization (WHO) recommends that all blood donations should be screened for infections prior to use. Screening for HIV, hepatitis B, hepatitis c, and syphilis should be mandatory.
Moreover, increase in R&D activities for development of novel chronic hepatitis B treatment, rise in the U. S. food & drug administration (FDA) approvals and novel product launch in the market by key players boost the market growth. For instance, in June 2022, glaxosmithkline (GSK), a science-led global healthcare company, announced the interim results from the B-Clear phase IIb trial showing that bepirovirsen, an investigational antisense oligonucleotide treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA after 24 weeks’ treatment in people with chronic hepatitis B (CHB). Furthermore, advancements in hepatitis B treatment and rise in diagnosis rate further contribute toward the market growth. However, high cost of chronic hepatitis B drugs is projected to hinder the growth of the market.
The chronic hepatitis B market is segmented on the basis of drug class, gender, distribution channel, and region. By drug class, the market is fragmented into antivirals, and immune modulators. By gender, the market is classified into male, and female. The male segment is further divided into adult and geriatric. The female segment is further divided into adult and geriatric. By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Biocon Inc, Cipla Limited, Dr. Reddy's Laboratories, Gilead Sciences, Inc., Novartis AG, Reliance Life Sciences, Sun Pharmaceutical Industries Limited, Teva pharmaceuticals, Viatris Inc and Zydus Cadila.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic hepatitis b (chb) market analysis from 2021 to 2031 to identify the prevailing chronic hepatitis b (chb) market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the chronic hepatitis b (chb) market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global chronic hepatitis b (chb) market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
- Antivirals
- Immune Modulators
By Gender
- Male
- Age Group
- Adult
- Geriartic
- Female
- Age Group
- Adult
- Geriartic
By Distribution Channel
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
By Region
- North America
- U. S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- GlaxoSmithKline (GSK)
- Gilead Sciences, Inc.
- Merck & Co. Inc.
- Bristol Myers Squibb Co.
- Teva Pharmaceutical Industries Limited
- zydus cadila
- Novartis AG
- F. Hoffman La Roche, Ltd.
- Viatris Inc. (Mylan NV)
- Cipla Ltd
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Antivirals
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Immune Modulators
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER
5.1 Overview
5.1.1 Market size and forecast
5.2 Male
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.2.4 Male Chronic Hepatitis B (CHB) Market by Age Group
5.2.4.1 Adult Market size and forecast, by region
5.2.4.2 Geriartic Market size and forecast, by region
5.3 Female
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.3.4 Female Chronic Hepatitis B (CHB) Market by Age Group
5.3.4.1 Adult Market size and forecast, by region
5.3.4.2 Geriartic Market size and forecast, by region
CHAPTER 6: CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug Stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: CHRONIC HEPATITIS B (CHB) MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.3 North America Market size and forecast, by Gender
7.2.3.1 North America Male Chronic Hepatitis B (CHB) Market by Age Group
7.2.3.2 North America Female Chronic Hepatitis B (CHB) Market by Age Group
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Market size and forecast, by Drug Class
7.2.5.1.2 Market size and forecast, by Gender
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Class
7.2.5.2.2 Market size and forecast, by Gender
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Class
7.2.5.3.2 Market size and forecast, by Gender
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.3 Europe Market size and forecast, by Gender
7.3.3.1 Europe Male Chronic Hepatitis B (CHB) Market by Age Group
7.3.3.2 Europe Female Chronic Hepatitis B (CHB) Market by Age Group
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Class
7.3.5.1.2 Market size and forecast, by Gender
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Class
7.3.5.2.2 Market size and forecast, by Gender
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Class
7.3.5.3.2 Market size and forecast, by Gender
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Class
7.3.5.4.2 Market size and forecast, by Gender
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Class
7.3.5.5.2 Market size and forecast, by Gender
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Class
7.3.5.6.2 Market size and forecast, by Gender
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.3 Asia-Pacific Market size and forecast, by Gender
7.4.3.1 Asia-Pacific Male Chronic Hepatitis B (CHB) Market by Age Group
7.4.3.2 Asia-Pacific Female Chronic Hepatitis B (CHB) Market by Age Group
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Class
7.4.5.1.2 Market size and forecast, by Gender
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Class
7.4.5.2.2 Market size and forecast, by Gender
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Drug Class
7.4.5.3.2 Market size and forecast, by Gender
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Drug Class
7.4.5.4.2 Market size and forecast, by Gender
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Class
7.4.5.5.2 Market size and forecast, by Gender
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Class
7.4.5.6.2 Market size and forecast, by Gender
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.3 LAMEA Market size and forecast, by Gender
7.5.3.1 LAMEA Male Chronic Hepatitis B (CHB) Market by Age Group
7.5.3.2 LAMEA Female Chronic Hepatitis B (CHB) Market by Age Group
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Class
7.5.5.1.2 Market size and forecast, by Gender
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Class
7.5.5.2.2 Market size and forecast, by Gender
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Class
7.5.5.3.2 Market size and forecast, by Gender
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Class
7.5.5.4.2 Market size and forecast, by Gender
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Players
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 GlaxoSmithKline (GSK)
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Gilead Sciences, Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Merck & Co. Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Bristol Myers Squibb Co.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Teva Pharmaceutical Industries Limited
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 zydus cadila
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novartis AG
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 F. Hoffman La Roche, Ltd.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Viatris Inc. (Mylan NV)
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Cipla Ltd
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
Executive Summary
According to this report, titled, 'Chronic Hepatitis B (CHB) Market,' the chronic hepatitis b (CHB) market was valued at $4.6 billion in 2021, and is estimated to reach $6.2 billion by 2031, growing at a CAGR of 3% from 2022 to 2031.Hepatitis B is a viral infection that causes liver inflammation and damage. Inflammation is swelling that occurs when tissues of the body become injured or infected. Inflammation can damage organs. Chronic hepatitis B is a long-lasting infection. According to National Institutes of Health (NIH), about 90% of infants infected with hepatitis B develop a chronic infection. About 25 to 50% of children infected between the ages of 1 and 5 years develop chronic infections. However, only about 5% of people first infected as adults develop chronic hepatitis B.
The surge in the prevalence of hepatitis B and improvements in healthcare infrastructure drive the growth of the Chronic Hepatitis B Market Size. For instance, in April 2022, according to Bristol Myers & Squibb, each year, nearly 1 million people worldwide died due to hepatitis B or hepatitis c. In addition, rise in awareness about hepatitis infection and advancements in hepatitis treatment boost the expansion of the Chronic Hepatitis B Industry.
The strict government regulations on blood transfusion and blood banks contribute to the growth of the Chronic Hepatitis B Market Size. The World Health Organization (WHO) recommends that all blood donations should be screened for infections prior to use. Screening for HIV, hepatitis B, hepatitis c, and syphilis should be mandatory. and initiatives taken by the government and non-government organizations propel the growth of the Chronic Hepatitis B Market Size.
Furthermore, Chronic Hepatitis B Market Trends that drive the growth of the chronic hepatitis B market include R&D for the development of chronic hepatitis B, an increase in drug class approvals, and new product launches in the market. In addition, advancements in the diagnosis of hepatitis B propel the growth of the market. For instance, in May 2022, Abbott, a leading pharmaceutical company, announced the launch of HBsAg Next Qualitative Assay for early detection of the Hepatitis B virus (HBV) in India. Early identification of HBV infections not only helps in preventing or delaying the progression of advanced liver diseases but also reduces the risk of transmission. Furthermore, the rise in healthcare expenditure and improvements in healthcare facilities in developing nations contribute to the growth of the Chronic Hepatitis B Industry.
The chronic hepatitis B market is segmented into drug class, gender, distribution channel, and region.
Based on the drug class segment, the market is divided into antivirals and immune modulators. The antivirals segment dominated the Chronic Hepatitis B Market Share in 2021, and this trend is expected to continue during the Chronic Hepatitis B Market Forecast period, owing to the increase in the prevalence of hepatitis B.
Based on gender segment, the market is categorized into male and female. The male segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to the high prevalence rate of male and an increase in blood transfusion rate.
Depending on the distribution channel segment, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores & retail pharmacies segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to an increase in healthcare expenditure and a rise in the number of drug stores & retail pharmacies.
North America accounted for a majority of the global chronic hepatitis B market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed to the rising prevalence of hepatitis B, the well-established healthcare infrastructure, and the presence of key players in the region. Asia-Pacific is anticipated to witness lucrative growth during the Chronic Hepatitis B Market Analysis period owing to an increase in the number of blood banks, growth in the geriatric population, and a high population base.
Key findings of the study
By drug class, the antivirals segment was the highest contributor to the Chronic Hepatitis B (CHB) Market in 2021.By gender, the male segment was the highest contributor to the Chronic Hepatitis B (CHB) Market in 2021.
By distribution channel, the drug stores & retail pharmacies segment was the highest contributor to the market in 2021.
Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period
Companies Mentioned
- GlaxoSmithKline (Gsk)
- Gilead Sciences, Inc.
- Merck & Co. Inc.
- Bristol Myers Squibb Co.
- Teva Pharmaceutical Industries Limited
- Zydus Cadila
- Novartis AG
- F. Hoffman La Roche, Ltd.
- Viatris Inc. (Mylan Nv)
- Cipla Ltd
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 290 |
| Published | October 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 4589.8 million |
| Forecasted Market Value ( USD | $ 6213.15 million |
| Compound Annual Growth Rate | 3.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
